Publication Density and Historical Breakdown

Title: Hypochondroplasia Scientific Bibliography 1964-2026

Link to Excel File  

The bibliography contains 593 deduplicated scientific materials, from 1964 through July 2026, including:

• 486 academic publications 
• 81 conference and pharmaceutical materials 
• 13 clinical-trial records 
• 7 clinical resources 
• 4 regulatory records 
• 2 research datasets 

Every item is enumerated with its publication date, title, authors or organisation, source, material type, identifiers and source links. 

Link to Sharepoint Library

Major hypochondroplasia medical milestones

1924: The condition received its enduring name.
André Léri and Alice Linossier introduced the term hypochondroplasie in their paper, Hypochondroplasie héréditaire. This was a foundational naming and classification milestone.
Source: https://books.google.com/books?id=eT1EAQAAIAAJ&pg=PA1780

1964: Early clinical and radiographic definition of hypochondroplasia.
Kazimierz Kozłowski and Czesław Zychowicz published an important paper that helped distinguish HCH from achondroplasia and other skeletal dysplasias.
Source: https://pubmed.ncbi.nlm.nih.gov/14337160/

1969–1971: HCH became firmly established as a distinct inherited skeletal dysplasia.
Family studies clarified its clinical characteristics, radiographic findings and autosomal-dominant inheritance.
Sources:
https://pubmed.ncbi.nlm.nih.gov/5783850/
https://pubmed.ncbi.nlm.nih.gov/5564166/

1994–1995: The genetic basis was discovered.
HCH was mapped to chromosome 4p16.3, and the common FGFR3 p.Asn540Lys variant was identified. This enabled molecular diagnosis, genetic counselling, family testing and prenatal testing.
Sources:
https://www.nature.com/articles/ng0394-318
https://www.nature.com/articles/ng0795-357

2012: Neurological involvement received major recognition.
Research linked HCH, particularly N540K-related HCH, with temporal-lobe abnormalities, epilepsy and neurodevelopmental difficulties. This strengthened the case for neurological and developmental monitoring.
Source: https://pubmed.ncbi.nlm.nih.gov/23165795/

2024: The first positive prospective trial of a targeted HCH treatment.
Vosoritide increased annualised growth velocity by approximately 1.81 cm per year and was generally well tolerated.
Source: https://pubmed.ncbi.nlm.nih.gov/38813446/

May 2026: The first successful pivotal Phase 3 trial in HCH.
CANOPY-HCH-3 reported a 2.33 cm-per-year improvement in annualised growth velocity compared with placebo, together with improvements in standing height and arm span. Vosoritide is not yet approved specifically for HCH.
Source: https://www.biomarin.com/news/press-releases/biomarin-announces-positive-phase-3-pivotal-study-results-for-voxzogo-vosoritide-in-children-with-hypochondroplasia/

July 2026: The lifelong medical complications of HCH was documented at population level.
A study of 549 people demonstrated substantial cardiovascular, respiratory, orthopaedic, ENT and mental-health burden. It strengthened the case for coordinated multidisciplinary care throughout life.
Source: https://www.sciencedirect.com/science/article/pii/S8756328226002425

Title: International guideline on genetic testing of children with short stature

Link

Abstract

Short stature may be caused by a multitude of conditions, including genetic and non-genetic factors such as hypochondroplasia. Over the last decade, advances in genetic sequencing technologies have revolutionized our understanding of the underlying physiology of growth and greatly increased our ability to identify genetic etiologies of short stature. This current guideline provides a general overview of the approach to evaluating a child with short stature, followed by recommendations that identify key factors in the medical and family history, physical examination, radiographic, and laboratory work-up which enhance the likelihood of identifying a genetic etiology. An algorithm is proposed for the genetic workup of individuals with short stature based on their clinical presentation. Additionally, the benefits and risks of genetic testing are discussed, along with references to relevant medical resources and research publications.

Title: Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia

Link

Abstract

Hypochondroplasia (HCH) is a disproportionate short-statured skeletal dysplasia condition caused by gain-of-function pathogenic variants in the fibroblast growth receptor 3 gene (FGFR3). Although HCH typically becomes clinically apparent after the first year of life, when height discrepancy compared with the general population becomes more pronounced, diagnosis is often delayed by several years. Early recognition of hypochondroplasia is challenging due to wide phenotypic variability and subtle clinical and radiographic features, which can lead to delayed or missed diagnosis. Additionally, the heterogeneity of variants and restrictive testing criteria can further contribute to diagnostic delays. Early diagnosis may facilitate timely clinical management and psychosocial support, but currently, there are no standardized diagnostic criteria for hypochondroplasia, nor are the diagnostic pathways well described in the medical resources and research publications.

Title: Parental Perception of Quality of Life and Impact of Short Stature in Children with Hypochondroplasia and Other Genetic Causes of Short Stature

Link

Abstract

Short stature, often seen in conditions such as hypochondroplasia and other genetic factors, can lead to physical limitations and socioemotional effects that impact both a child's and parents' quality of life (QoL). This study aims to explore the influence of these genetic causes, including ACAN, NPR2 mutations, and RASopathy, on QoL, utilizing various medical resources and relevant research publications.

Title: Living With Hypochondroplasia: A Qualitative Exploration of Children's and Caregivers' Experiences, Challenges, and Unmet Needs

Link

Abstract

Hypochondroplasia (HCH) is a rare genetic skeletal dysplasia characterized by short stature, disproportionate limbs, and associated complications such as learning differences. Currently, there are no approved medical resources to address HCH-related short stature, which can significantly impact quality of life. This study aimed to explore diagnostic processes, care pathways, daily life impacts, and the unmet needs of individuals affected by hypochondroplasia, contributing to the body of research publications in this field.

Title: The Head Circumference Height Index (HCH-I) to Quantify Relative Macrocephaly and Aid Identification of Hypochondroplasia in Children

Link

Abstract

Hypochondroplasia (HCH) is a rare skeletal dysplasia resulting from pathogenic variants in the FGFR3 gene. In our research publications, we hypothesized that the relative disproportion between head circumference and height in HCH could be diagnostically informative. Therefore, we developed a simple index of head-stature disproportion to assist pediatricians in diagnosing hypochondroplasia effectively.

Title: Growth Reference Charts for Children with Hypochondroplasia

Link: Growth reference charts for children with hypochondroplasia Cheung et al. 2024

Abstract

Hypochondroplasia (HCH) is a rare skeletal dysplasia characterized by mild short stature. There is a lack of comprehensive growth reference charts specifically for this population, which highlights the need for better medical resources. To address this gap, anthropometric data were collected to create height, weight, and head circumference (HC) growth reference charts for children diagnosed with HCH. Mixed longitudinal anthropometric data, alongside genetic analysis results, were gathered from 14 specialized skeletal dysplasia centers across Europe. Growth charts were developed using Generalized Additive Models for Location, Scale, and Shape. Measurements for height (983), weight (896), and HC (389) were compiled from 188 children (79 female) aged 0-18 years with a diagnosis of HCH. Among the 84 children who underwent genetic testing, a pathogenic variant in FGFR3 was identified in 92% (77). This data was utilized to generate growth references for height, weight, and HC, depicted as charts featuring seven centiles ranging from the 2nd to the 98th, for ages 0-4 and 0-16 years. The development of HCH-specific growth charts is crucial in the clinical care of these children. These charts assist in identifying potential comorbidities that may impact growth and development and serve as a vital benchmark for future research publications and interventional studies.

Title: Vosoritide treatment for children with hypochondroplasia: a phase 2 trial

Link

Abstract

Hypochondroplasia is a rare autosomal dominant skeletal dysplasia due to activating variants in FGFR3. It presents with disproportionate short stature with a wide range of clinical severity. There are currently no approved medications to treat short stature in children with hypochondroplasia. Vosoritide is a C-type natriuretic peptide analog that was recently approved for improving growth in children with achondroplasia. We aimed to evaluate the safety and efficacy of vosoritide in children with hypochondroplasia.